Concepts (62)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lichen Sclerosus et Atrophicus | 1 | 2018 | 7 | 0.350 |
Why?
|
| Vitiligo | 1 | 2018 | 16 | 0.340 |
Why?
|
| Calcineurin Inhibitors | 1 | 2018 | 55 | 0.330 |
Why?
|
| Glucocorticoids | 1 | 2018 | 343 | 0.280 |
Why?
|
| Drug Eruptions | 1 | 2014 | 35 | 0.270 |
Why?
|
| Vaccines | 1 | 2014 | 70 | 0.250 |
Why?
|
| Acrodermatitis | 1 | 2013 | 3 | 0.240 |
Why?
|
| Leg Dermatoses | 1 | 2013 | 7 | 0.240 |
Why?
|
| Facial Dermatoses | 1 | 2013 | 11 | 0.240 |
Why?
|
| p21-Activated Kinases | 1 | 2011 | 15 | 0.210 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2011 | 48 | 0.210 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2011 | 54 | 0.210 |
Why?
|
| Estrogen Receptor alpha | 1 | 2011 | 138 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2009 | 16 | 0.190 |
Why?
|
| Oxides | 1 | 2009 | 43 | 0.180 |
Why?
|
| Arsenicals | 1 | 2009 | 47 | 0.180 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 277 | 0.170 |
Why?
|
| Genitalia | 1 | 2018 | 19 | 0.090 |
Why?
|
| Administration, Topical | 1 | 2018 | 92 | 0.090 |
Why?
|
| Anal Canal | 1 | 2018 | 56 | 0.080 |
Why?
|
| Skin Pigmentation | 1 | 2018 | 38 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2756 | 0.080 |
Why?
|
| Smallpox Vaccine | 1 | 2014 | 11 | 0.070 |
Why?
|
| Skin | 1 | 2018 | 541 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2011 | 1545 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1499 | 0.060 |
Why?
|
| Buttocks | 1 | 2013 | 10 | 0.060 |
Why?
|
| Arm | 1 | 2013 | 92 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2011 | 10 | 0.050 |
Why?
|
| Pyrones | 1 | 2011 | 8 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 3569 | 0.050 |
Why?
|
| Quinolines | 1 | 2011 | 90 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2011 | 501 | 0.050 |
Why?
|
| Tosyl Compounds | 1 | 2009 | 14 | 0.050 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2009 | 14 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2011 | 778 | 0.050 |
Why?
|
| Response Elements | 1 | 2009 | 61 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 104 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 869 | 0.040 |
Why?
|
| Anilides | 1 | 2009 | 45 | 0.040 |
Why?
|
| Nitriles | 1 | 2009 | 140 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2009 | 91 | 0.040 |
Why?
|
| Androgens | 1 | 2009 | 146 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2009 | 305 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2009 | 124 | 0.040 |
Why?
|
| Humans | 5 | 2018 | 81308 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 630 | 0.040 |
Why?
|
| Protein Transport | 1 | 2009 | 408 | 0.040 |
Why?
|
| RNA | 1 | 2011 | 522 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 1039 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 744 | 0.040 |
Why?
|
| Female | 3 | 2018 | 42685 | 0.040 |
Why?
|
| Child | 1 | 2018 | 6639 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2009 | 572 | 0.040 |
Why?
|
| Infant | 1 | 2013 | 2965 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 1120 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 2330 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2018 | 7600 | 0.030 |
Why?
|
| Protein Binding | 1 | 2009 | 1451 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 2332 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1537 | 0.020 |
Why?
|
| Male | 1 | 2009 | 39770 | 0.010 |
Why?
|